HIGHLIGHTS
- who: Haige Ye from the A phase I/Ib study from , to , conducted in Ohio State University demonstrated that ibrutinib in combination with bendamustine and rituximab in , patients with, cell lymphoma, which included , patients have published the research: Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy, in the Journal: (JOURNAL)
- what: In this review, the authors focus on the various treatment strategies available for treatment of MCL in young, fit individuals and assess the efficacy of each treatment option to determine the paramount therapy for MCL in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.